Drugs / HX15001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06999720 | Jun 2025 → Sep 2026 overdue | — | Helixon Biotechnology (Suzhou) Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HX15001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06999720 ↗ |
| Route | Subcutaneous | “subcutaneous doses of HX15001 or placebo” NCT06999720 ↗ |